title: Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review).
abstract: Oxaliplatin is effective for the treatment of advanced colorectal cancer; however, its application is restricted due to its dose-limiting toxicity. Liposomes are sphere-shaped vesicles consisting of one or more phospholipid bilayers. Liposomes as drug carriers are characterized by delayed release, lesion targeting and may be used as a drug-delivery system to decrease the side effects of cytotoxic drugs. Active targeting modification of liposomes may change the biological distribution of the anticancer agents, reduce or reverse multidrug resistance of tumor cells and enhance the effects of anticancer therapy. Based on the characteristics mentioned above, the aim of the present review was to demonstrate that polyethylene glycol-liposomes containing oxaliplatin may offer advantages for the treatment of colorectal cancer in clinical practice.
authors.affiliation: Department of General Surgery, Third People's Hospital of Mianyang, Mianyang, Sichuan 621000, P.R. China ; Department of Gastrointestinal Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing 400016, P.R. China.
authors.forename: Chuang
authors.initials: C
authors.lastname: Yang
authors.affiliation: Department of Gastrointestinal Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing 400016, P.R. China.
authors.forename: Zhong-Xue
authors.initials: ZX
authors.lastname: Fu
keywords: colorectal cancer; drug delivery system; liposomes; oxaliplatin
references.citation: Pharmaceutics. 2013 Apr 23;5(2):246-60
references.pmid: 24300449
references.citation: Eur J Pharm Biopharm. 2012 Aug;81(3):524-31
references.pmid: 22554766
references.citation: Drugs Aging. 1999 Jun;14(6):459-75
references.pmid: 10408744
references.citation: Int J Pharm. 2014 Jan 1;459(1-2):30-9
references.pmid: 24239579
references.citation: Crit Rev Biomed Eng. 2012;40(1):21-41
references.pmid: 22428797
references.citation: Cell Biol Int. 2012 Mar 1;36(3):289-96
references.pmid: 21888623
references.citation: World J Gastrointest Oncol. 2013 Dec 15;5(12):207-21
references.pmid: 24363829
references.citation: Cancer Res. 2013 Apr 15;73(8):2412-7
references.pmid: 23423979
references.citation: Expert Opin Drug Deliv. 2014 Jan;11(1):83-100
references.pmid: 24320104
references.citation: BMC Biotechnol. 2011 Mar 15;11:21
references.pmid: 21401960
references.citation: Nanomedicine. 2010 Feb;6(1):179-90
references.pmid: 19447205
references.citation: Drugs. 2003;63(19):2127-56
references.pmid: 12962525
references.citation: Eur J Pharm Biopharm. 2009 Mar;71(3):409-19
references.pmid: 19070661
references.citation: Clin Colorectal Cancer. 2010 Dec;9(5):297-304
references.pmid: 21208844
references.citation: Chem Phys Lipids. 2014 Jan;177:8-18
references.pmid: 24220497
references.citation: J Control Release. 2010 Mar 3;142(2):167-73
references.pmid: 19861140
references.citation: J Nucl Med. 2003 Apr;44(4):610-7
references.pmid: 12679407
references.citation: Eur J Pharm Biopharm. 2014 May;87(1):142-51
references.pmid: 24361534
references.citation: Tumori. 2003 May-Jun;89(3):237-49
references.pmid: 12908776
references.citation: Int J Nanomedicine. 2013;8:4659-71
references.pmid: 24353415
references.citation: Clin Colorectal Cancer. 2012 Jun;11(2):93-100
references.pmid: 22154408
references.citation: Methods Mol Biol. 2010;624:25-37
references.pmid: 20217587
references.citation: Pharmaceutics. 2013 Oct 25;5(4):542-69
references.pmid: 24300562
references.citation: Invest New Drugs. 2011 Dec;29(6):1321-7
references.pmid: 20658169
references.citation: Oncol Rep. 2012 Sep;28(3):1006-12
references.pmid: 22710431
references.citation: Oncol Rep. 2011 Jun;25(6):1621-8
references.pmid: 21455585
references.citation: Indian J Pharm Sci. 2013 Jul;75(4):420-6
references.pmid: 24302796
references.citation: Nanotechnology. 2013 Oct 11;24(40):405101
references.pmid: 24029287
references.citation: Int J Nanomedicine. 2006;1(3):297-315
references.pmid: 17717971
references.citation: Tidsskr Nor Laegeforen. 2003 Nov 20;123(22):3198-200
references.pmid: 14714007
references.citation: Ann Oncol. 2013 Jul;24(7):1769-1777
references.pmid: 23559149
references.citation: Nihon Rinsho. 1998 Mar;56(3):657-62
references.pmid: 9549352
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):454-64
references.pmid: 22065082
references.citation: Nan Fang Yi Ke Da Xue Xue Bao. 2013 Dec;33(12):1815-8
references.pmid: 24369252
references.citation: Cancer Chemother Pharmacol. 2013 Jun;71(6):1463-72
references.pmid: 23543295
references.citation: Anticancer Drugs. 2010 Sep;21(8):737-48
references.pmid: 20631611
references.citation: Biol Pharm Bull. 2013;36(11):1842-8
references.pmid: 24189428
references.citation: Anticancer Agents Med Chem. 2010 May;10(4):293-301
references.pmid: 20187870
references.citation: Biochem J. 2004 Jan 1;377(Pt 1):159-69
references.pmid: 14505488
references.citation: Yao Xue Xue Bao. 2013 Jul;48(7):1142-7
references.pmid: 24133983
references.citation: Nanotechnology. 2011 Oct 14;22(41):415103
references.pmid: 21914940
references.citation: Nanomedicine (Lond). 2013 Sep;8(9):1529-48
references.pmid: 23987112
references.citation: Mol Cancer Ther. 2009 Jan;8(1):10-6
references.pmid: 19139108
references.citation: Eur J Pharm Biopharm. 2012 Jun;81(2):273-80
references.pmid: 22369879
references.citation: Annu Rev Biophys Bioeng. 1978;7:435-68
references.pmid: 352245
references.citation: Clin Transl Oncol. 2010 Aug;12(8):533-42
references.pmid: 20709651
references.citation: Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28
references.pmid: 20061178
references.citation: Exp Oncol. 2012 Jul;34(2):101-6
references.pmid: 23013761
references.citation: Cancer Sci. 2010 Nov;101(11):2470-5
references.pmid: 20731663
references.citation: J Control Release. 2012 Dec 28;164(3):265-75
references.pmid: 22800576
references.citation: Iran J Pharm Res. 2013 Winter;12(Suppl):3-10
references.pmid: 24250666
references.citation: J Control Release. 2012 Jan 10;157(1):118-25
references.pmid: 21827801
references.citation: Curr Drug Deliv. 2007 Oct;4(4):297-305
references.pmid: 17979650
references.citation: Cancer Lett. 2003 Jul 18;197(1-2):199-204
references.pmid: 12880982
references.citation: Int J Pharm Investig. 2011 Jan;1(1):35-41
references.pmid: 23071918
references.citation: Nanoscale Res Lett. 2013 Feb 22;8(1):102
references.pmid: 23432972
references.citation: JAMA. 2012 Apr 4;307(13):1383-93
references.pmid: 22474202
references.citation: Trends Biotechnol. 2014 Jan;32(1):32-45
references.pmid: 24210498
references.citation: Pharm Res. 2013 Jun;30(6):1597-607
references.pmid: 23386106
references.citation: Cancer Detect Prev. 2003;27(3):229-38
references.pmid: 12787731
references.citation: Expert Opin Drug Deliv. 2011 Aug;8(8):1025-40
references.pmid: 21663539
references.citation: J Toxicol. 2011;2011:152474
references.pmid: 21876690
references.citation: Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
references.pmid: 23036225
references.citation: N Engl J Med. 2013 Sep 12;369(11):1023-34
references.pmid: 24024839
references.citation: Eur Rev Med Pharmacol Sci. 2012 Sep;16(9):1211-7
references.pmid: 23047504